CVRX Logo

CVRx, Inc. (CVRX) 

NASDAQ
Market Cap
$353.52M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
165 of 774
Rank in Industry
21 of 99

Largest Insider Buys in Sector

CVRX Stock Price History Chart

CVRX Stock Performance

About CVRx, Inc.

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated …

Insider Activity of CVRx, Inc.

Over the last 12 months, insiders at CVRx, Inc. have bought $322,508 and sold $151,890 worth of CVRx, Inc. stock.

On average, over the past 5 years, insiders at CVRx, Inc. have bought $15.87M and sold $119,052 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Hykes Kevin (PRES & CEO) — $250,767. SLATTERY JOSEPH P (director) — $143,482.

The last purchase of 3,000 shares for transaction amount of $24,300 was made by SLATTERY JOSEPH P (director) on 2024‑08‑15.

List of Insider Buy and Sell Transactions, CVRx, Inc.

2024-08-15Purchasedirector
3,000
0.0133%
$8.10$24,3000.00%
2024-08-08Purchasedirector
3,000
0.0134%
$8.24$24,716+2.59%
2024-08-06Purchasedirector
2,500
0.0115%
$9.09$22,725-3.98%
2024-08-05PurchasePRES & CEO
30,000
0.1373%
$8.36$250,767+2.72%
2024-02-20SaleCHIEF MKTG & STRAT OFFICER
2,545
0.0121%
$21.91$55,748-55.76%
2024-02-16Sale10 percent owner
3,725
0.0203%
$25.81$96,142-56.72%
2023-08-03SaleCHIEF MKTG & STRAT OFFICER
628
0.0031%
$18.55$11,652-4.31%
2023-07-31SaleCHIEF MKTG & STRAT OFFICER
1,122
0.0056%
$17.49$19,629-2.90%
2022-11-28SaleCHIEF MKTG & STRAT OFFICER
4,600
0.023%
$11.94$54,931+27.16%
2022-05-24Purchase
8,070
0.0378%
$5.05$40,752+81.37%
2022-05-19Purchase
10,976
0.0534%
$5.04$55,297+87.72%
2022-05-03Purchase
3,992
0.0194%
$6.00$23,936+54.82%
2022-04-28Purchase
41,988
0.1855%
$5.97$250,673+40.06%
2022-02-28Purchasedirector
600
0.003%
$9.03$5,420-5.13%
2022-02-24Purchasedirector
3,400
0.0158%
$8.24$28,010-3.59%
2022-02-23Purchasedirector
38,200
0.1877%
$8.04$307,143+4.13%
2022-02-22Purchasedirector
40,008
0.1932%
$7.94$317,660+3.23%
2022-02-18Purchasedirector
26,659
0.1289%
$7.92$211,227+3.43%
2021-11-19Purchasedirector
600
0.006%
$13.69$8,213-38.88%
2021-11-18Purchasedirector
1,750
0.0172%
$14.63$25,607-43.58%

Insider Historical Profitability

<0.0001%
SLATTERY JOSEPH Pdirector
30645
0.1263%
$14.5730
Hykes KevinPRES & CEO
30000
0.1236%
$14.5710
NEW ENTERPRISE ASSOCIATES 10 L P10 percent owner
2026083
8.3503%
$14.5710<0.0001%
NEA PARTNERS 10 L P10 percent owner
2026083
8.3503%
$14.5710<0.0001%
Pardo Geoffrey Bdirector
1829022
7.5381%
$14.5710<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Johnson & Johnson$74.72M194.1M+17.39%+$11.07M1.75
Nea Management Company Llc$43.17M10.982.37M0%+$00.2
BlackRock$13.93M3.54764,999-4.78%-$699,901.31<0.0001
Balyasny Asset Management Llc$11.26M2.86618,530+51.97%+$3.85M0.03
The Vanguard Group$10.82M2.75594,312+5.64%+$577,621.17<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.